Skip to main content

Table 1 Demographic and clinical characteristics of study subjects

From: Involvement of lncRNA IL21-AS1 in interleukin-2 and T follicular regulatory cell activation in systemic lupus erythematosus

  SLE (n = 53) RA (n = 52) HD (n = 23)
Age (years) 40.9 ± 17.8 64.3 ± 15.7 38.1 ± 8.0
Females, n (%) 49 (92.5) 35 (67.3) 20 (87.0)
Disease duration (months) 140.4 ± 159.9 83.6 ± 127.1  
SLEDAI score 4.9 ± 5.4   
BILAG score 4.8 ± 6.6   
Anti-dsDNA (U/ml) 34.4 ± 82.9   
IgG (mg/dl) 1657 ± 710.8 1374 ± 396.3  
CH50 (U/ml) 42.7 ± 14.1   
C3 (mg/dl) 84.7 ± 29.2   
C4 (mg/dl) 16.7 ± 9.1   
CRP (mg/dl) 0.2 ± 0.4 1.5 ± 2.0  
ESR (mm/h) 36.0 ± 31.3 42.0 ± 28.1  
Prednisolone use at baseline, n (%) 36 (67.9) 18 (34.6)  
Dose of prednisolone (mg/day) 3.1 ± 3.3 3.8 ± 9.6  
Hydroxychloroquine use at baseline, n (%) 30 (56.6)   
Immunosuppressant use at baseline
 Mycophenolate mofetil, n (%) 10 (18.9)   
 Calcineurin inhibitors, n (%) 9 (17.0)   
 Azathioprine, n (%) 4 (7.5)   
 Methotrexate, n (%) 2 (3.8) 36 (69.2)  
 Mizoribine, n (%) 2 (3.8)   
 Leflunomide, n (%) 1 (1.9)   
  1. Data are mean ± SD or percentage of patients
  2. SLEDAI Systemic Lupus Erythematosus Disease Activity Index, BILAG British Isle Lupus Assessment Group, Anti-dsDNA Anti-double-stranded DNA antibody, CRP C-reactive protein, ESR Erythrocyte sedimentation rate